Long-Acting HIV Treatment and Prevention Are Coming: Preparing for Potential Game Changers (Overview)

On July 16, 2018, amfAR, The Foundation for AIDS Research, released four reports, Long-Acting HIV Treatment and Prevention Are Coming: Preparing for Potential Game Changers, prepared by O’Neill Institute scholars Jeffrey S. Crowley and Sean E. Bland. The reports highlight the education and policy dialogues needed to prepare for innovative long-acting products under development to treat and prevent HIV infection. 

The four reports include: (1) an overview, summarizing the need for and major policy issues related to extending access to new long-acting products for HIV treatment and prevention; (2) From Laboratory to Marketplace, discussing the Food and Drug Administration (FDA) review and approval process and special considerations for long-acting products; (3) Assessing the Payer Landscape, exploring the laws and policies that shape pharmaceutical access in public and private insurance; and (4) Defining the Intended Market for New Products, addressing issues such as adherence to non-daily products, consumer and provider acceptability, and cost-effectiveness. In addition to the reports, there is also a chart of long-acting agents in development for HIV treatment and prevention.

Read all four reports in this series here.